ArticleSurgical endoscopy2026
Minimally invasive radical surgery for gallbladder cancer: a single-unit experience of over 200 patients.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost published studies on minimally invasive radical cholecystectomy (MIRC) for gallbladder cancer (GBC) are limited by a small sample size, disproportionately high incidental GBC patients, and a lack of long-term outcomes. The present study aims to report the long-term oncological outcomes of MIRC in a large series of primary and locally advanced GBC patients.
methodsA retrospective analysis was conducted using prospectively collected data from primary and incidental GBC patients who underwent MIRC between March 2011 and June 2023. Patients who underwent MIRC and had benign pathology on final histopathological examination were excluded from the analysis. Perioperative short- and long-term oncological outcomes were analyzed.
resultsDuring the study period, 222 patients with suspected GBC underwent MIRC. The mean age was 49.5 ± 12.5 years with a female-to-male ratio of 4.2:1. The mean operative time and blood loss were 232 ± 55.3 min and 153.8 ± 68.4 mL, respectively. 205 patients with malignancy on final histopathology were included in the analysis of oncological outcomes. The overall median (95% CI) survival, 3-year and 5-year survival rates were 60 (41-62) months, 62.3% and 42.9%, respectively. The median survival was significantly higher in early-stage (T1/T2) GBC compared to locally advanced (T3/T4) tumors (66 vs. 36 months, P < 0.0001). Also, node-negative GBC patients had better overall survival than node-positive tumors (68 vs. 34 months, P < 0.0001). None of the patients had port-site recurrence.
conclusionThe largest single-unit series published to date documents the oncological efficacy of MIRC for GBC.
Indexed as
Identifiers
41131380What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.